{"nctId":"NCT01454531","briefTitle":"An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy","startDateStruct":{"date":"2011-06"},"conditions":["Allergic Rhinoconjunctivitis"],"count":199,"armGroups":[{"label":"AVANZ Phleum pratense","type":"EXPERIMENTAL","interventionNames":["Drug: AVANZ Phleum pratense"]}],"interventions":[{"name":"AVANZ Phleum pratense","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of grass pollen rhinoconjunctivitis\n* Positive SPT to Phleum pratense\n* Positive specific IgE against Phleum pratense\n\nExclusion Criteria:\n\n* Uncontrolled severe asthma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Subjects With Adverse Drug Reactions","description":"Frequency of patients with adverse reactions, local or systemic","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Subjects With Systemic Reactions","description":"Frequency of patients with systemic reactions, based on EAACI classification: Grade I (mild systemic reaction) to IV (anaphylactic shock)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Subjects With Local Adverse Reaction","description":"Frequency of patients with local adverse reactions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Phleum Pratense Specific IgE-blocking Factor","description":"IgE-blocking factor measures the amount of IgE bound to the allergen in the presence of allergen-competing factors present in the serum of a subject treated with allergen immunotherapy. The test is based in a double IgE measurement, an ordinary assay and an assay in the presence of competing components and takes the form of:\n\nIgE blocking factor = 1 - (Competitive IgE/Ordinary IgE). Theoretical limits are from 0 (no IgE blocked) to 1 (all IgE blocked) and, being a ratio, is a dimensionless measure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Phleum Pratense Specific IgG4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Immediate Cutaneous Response to Phleum Pratense","description":"Wheal size provoked after prick test with 4, 20 and 100 Âµg/ml Phl p 5 allergen extracts analysed by Parallel Line Assay. Cutaneous Tolerance Index (CTI) is the factor it is necessary to multiply the extract concentration by after SCIT (V6) to obtain the same response in terms of wheal area as at baseline (V1). CTI, being an index, is a dimensionless measure. A CTI of 1 indicates no change in skin sensitivity while if higher than 1 a decrease in skin sensitivity (it would be needed a more concentrated allergen extract at V6 to elicit the same skin response as at V1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":192},"commonTop":["Local reactions","Urticaria","Rhinitis allergic","Hypersensitivity"]}}}